Clinical Trials Browser

Phase 1/2 × Mesothelioma × Cyclophosphamide × Clear all

NCT02414269 2025-10-08

Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin

Phase 1/2 Active not recruiting

113 enrolled

BreastOther solid neoplasmThoracic

Breast Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis

NCT03907852 2025-08-27

Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

57 enrolled

GastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Cholangiocarcinoma

NCT05451849 2025-08-27

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

Phase 1/2 Active not recruiting

6 enrolled

BreastGastrointestinalGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

Phase 1/2 Terminated

15 enrolled 14 charts

GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT01362790 2019-06-06

SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

Phase 1/2 Completed

55 enrolled 22 charts

GastrointestinalOther solid neoplasmThoracic

Adenocarcinoma of Lung, Mesothelioma, Pancreatic Neoplasms